Systemic sclerosis associated with interstitial lung disease research hub

A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PRA023 in Subjects with Systemic Sclerosis Associated with Interstitial Lung Disease (SSc-ILD)

This study tests an experimental drug called tulisokibart for people with scleroderma that has caused lung scarring. Scleroderma can make breathing difficult. Researchers want to see if this medicine, given by a drip, safely slows down lung damage and improves breathing over 50 weeks compared to a dummy treatment.